What research findings exist regarding P021 in learning, memory, cognition, and neural plasticity?
P021 prevents some cognitive and synaptic function deficits. Other research reports: P021 improves subsequent cognitive function, tau, and amyloid pathology markers.[1] ↗ [2] ↗
Currently, 4 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2021 · PMID 34057082 | 3xTg-AD mice; early postnatal dietary administration | P021 prevents some cognitive and synaptic function deficits. | Early developmental intervention is not equivalent to treatment of patients who have already developed the disease in old age. |
| 2020 · PMID 32854771 | 3xTg-AD mice; prenatal to early postnatal period | P021 improves subsequent cognitive function, tau, and amyloid pathology markers. | 2020 developmental stage intervention; cannot extrapolate to use by pregnant women or infants. |
| 2017 · PMID 28655344 | 3xTg-AD mice; long-term dietary P021 intervention | Improves cognitive, dendritic, and synaptic indicators, and enhances neurogenesis. | Diseased mice, early long-term intervention; cannot be extrapolated to cognitive improvement in healthy humans. |
| 2014 · PMID 25046994 | 3xTg-AD mice; 12-month oral P021 study | Improves cognition, neurogenesis, and synaptic plasticity, reducing some tau-related pathology. | Animal AD model; cannot extrapolate to human treatment, not all pathological endpoints were confirmed to improve. |
References
What changes occurred in cognitive and synaptic markers following early P021 intervention?
P021 prevents some cognitive and synaptic function deficits.[1] ↗
3xTg-AD mice; early postnatal dietary administration
Early developmental intervention is not equivalent to treatment of patients who have already developed the disease in old age.
View the Article Title and Full Citation＋
Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction.
Journal of Alzheimer's Disease: JAD · Volume/Issue/Year 2021
First published 2021-01-01 · PMID 34057082
DOI 10.3233/JAD-201599
What statements can be supported by perinatal P021 animal interventions?
P021 improves subsequent cognitive function, tau, and amyloid pathology markers.[2] ↗
3xTg-AD mice; prenatal to early postnatal period
2020 developmental stage intervention; cannot extrapolate to use by pregnant women or infants.
View the Article Title and Full Citation＋
Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice.
Alzheimer's Research & Therapy · Volume and Year 2020
First published 2020-08-27 · PMID 32854771
DOI 10.1186/s13195-020-00666-7
What cognitive changes are observed with long-term P021 intervention?
Improves cognitive, dendritic, and synaptic indicators, and enhances neurogenesis.[3] ↗
3xTg-AD mice; long-term dietary P021 intervention
Diseased mice, early long-term intervention; cannot be extrapolated to cognitive improvement in healthy humans.
View the Article Title and Full Citation＋
Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound.
Alzheimer's Research & Therapy · Volume and Year 2017
First published 2017-06-27 · PMID 28655344
DOI 10.1186/s13195-017-0273-7
What Research Findings Exist on Cognition and Synaptic Indicators?
Improves cognition, neurogenesis, and synaptic plasticity, reducing some tau-related pathology.[4] ↗
3xTg-AD mice; 12-month oral P021 study
Animal AD model; cannot extrapolate to human treatment, not all pathological endpoints were confirmed to improve.
View the Article Title and Full Citation＋
Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease.
Neurobiology of disease · Volume/Issue Year 2014
First published on 2014-07-15 · PMID 25046994
DOI 10.1016/j.nbd.2014.07.001
Common issues and corresponding evidence
What research findings exist regarding P021 in learning, memory, cognition, and neural plasticity?＋
P021 prevents some cognitive and synaptic function deficits. Other research reports: P021 improves subsequent cognitive function, tau, and amyloid pathology markers.[1] ↗ [2] ↗
Can cognitive studies of P021 be used to enhance memory in healthy individuals?＋
No. Current data are mainly on AD-like mice, early or long-term interventions; improvements in cognition and synaptic indicators do not equal effects in healthy humans, and cannot be applied to pregnant women or infants.[1] ↗ [3] ↗ [4] ↗
P021—these conclusions apply to which study populations?＋
3xTg-AD mice; early postnatal dietary administration; 3xTg-AD mice; prenatal to early postnatal period; 3xTg-AD mice; long-term dietary P021 intervention. Early developmental intervention is not the same as treating elderly patients who are already symptomatic.[1] ↗ [2] ↗ [3] ↗
P021
Return to catalog specifications and batch file verification entry.
